BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17066453)

  • 1. Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.
    Novak H; Noy R; Oved K; Segal D; Wels WS; Reiter Y
    Int J Cancer; 2007 Jan; 120(2):329-36. PubMed ID: 17066453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
    Lev A; Noy R; Oved K; Novak H; Segal D; Walden P; Zehn D; Reiter Y
    Proc Natl Acad Sci U S A; 2004 Jun; 101(24):9051-6. PubMed ID: 15184663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules.
    Noy R; Haus-Cohen M; Oved K; Voloshin T; Reiter Y
    Mol Cancer Ther; 2015 Jun; 14(6):1327-35. PubMed ID: 25852061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
    Lev A; Novak H; Segal D; Reiter Y
    J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments.
    Robert B; Guillaume P; Luescher I; Doucey MA; Cerottini JC; Romero P; Mach JP
    Cancer Immun; 2001 Mar; 1():2. PubMed ID: 12747763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
    Donda A; Cesson V; Mach JP; Corradin G; Primus FJ; Robert B
    Cancer Immun; 2003 Aug; 3():11. PubMed ID: 12916958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
    Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
    Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
    Oved K; Lev A; Noy R; Segal D; Reiter Y
    Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.
    Kubach J; Hubo M; Amendt C; Stroh C; Jonuleit H
    Int J Cancer; 2015 Feb; 136(4):821-30. PubMed ID: 24947844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of HIV gp120-specific cytolytic T lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector.
    Carbonetti NH; Tuskan RG; Lewis GK
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):819-27. PubMed ID: 11429123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules.
    Newberg MH; Ridge JP; Vining DR; Salter RD; Engelhard VH
    J Immunol; 1992 Jul; 149(1):136-42. PubMed ID: 1607650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
    Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
    Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
    Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
    J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
    Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
    Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
    Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.